193 related articles for article (PubMed ID: 12969089)
41. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
42. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients.
Yang X; Tan P; Song L; Lu Z
Am J Ther; 2016; 23(6):e1436-e1441. PubMed ID: 25923229
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
[TBL] [Abstract][Full Text] [Related]
44. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Gisbert JP; Castro-Fernández M; Bermejo F; Pérez-Aisa A; Ducons J; Fernández-Bermejo M; Bory F; Cosme A; Benito LM; López-Rivas L; Lamas E; Pabón M; Olivares D;
Am J Gastroenterol; 2006 Feb; 101(2):243-7. PubMed ID: 16454825
[TBL] [Abstract][Full Text] [Related]
45. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Li Y; Huang X; Yao L; Shi R; Zhang G
Wien Klin Wochenschr; 2010 Jul; 122(13-14):413-22. PubMed ID: 20628905
[TBL] [Abstract][Full Text] [Related]
46. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
47. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
Hassan C; De Francesco V; Zullo A; Scaccianoce G; Piglionica D; Ierardi E; Panella C; Morini S
Aliment Pharmacol Ther; 2003 Sep; 18(6):641-6. PubMed ID: 12969091
[TBL] [Abstract][Full Text] [Related]
48. [The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication].
Lee JH; Hong SP; Kwon CI; Phyun LH; Lee BS; Song HU; Ko KH; Hwang SG; Park PW; Rim KS; Kim S
Korean J Gastroenterol; 2006 Jul; 48(1):19-24. PubMed ID: 16861877
[TBL] [Abstract][Full Text] [Related]
49. Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments.
Sapmaz F; Kalkan IH; Güliter S; Atasoy P
Eur J Intern Med; 2014 Mar; 25(3):224-9. PubMed ID: 24268371
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
51. A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates.
Sotudehmanesh R; Malekzadeh R; Fazel A; Massarrat S; Ziad-Alizadeh B; Eshraghian MR
J Gastroenterol Hepatol; 2001 Mar; 16(3):264-8. PubMed ID: 11339416
[TBL] [Abstract][Full Text] [Related]
52. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Gisbert JP; Gisbert JL; Marcos S; Grávalos RG; Carpio D; Pajares JM
Aliment Pharmacol Ther; 1999 Oct; 13(10):1311-6. PubMed ID: 10540045
[TBL] [Abstract][Full Text] [Related]
53. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Graham DY; Belson G; Abudayyeh S; Osato MS; Dore MP; El-Zimaity HM
Dig Liver Dis; 2004 Jun; 36(6):384-7. PubMed ID: 15248377
[TBL] [Abstract][Full Text] [Related]
54. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Chung JW; Lee JH; Jung HY; Yun SC; Oh TH; Choi KD; Song HJ; Lee GH; Kim JH
Helicobacter; 2011 Aug; 16(4):289-94. PubMed ID: 21762268
[TBL] [Abstract][Full Text] [Related]
55. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Fallone CA; Chiba N; van Zanten SV; Fischbach L; Gisbert JP; Hunt RH; Jones NL; Render C; Leontiadis GI; Moayyedi P; Marshall JK
Gastroenterology; 2016 Jul; 151(1):51-69.e14. PubMed ID: 27102658
[TBL] [Abstract][Full Text] [Related]
56. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Lu B; Wang J; Li J; Liu L; Chen Y
Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
[TBL] [Abstract][Full Text] [Related]
57. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
Hung IF; Chan P; Leung S; Chan FS; Hsu A; But D; Seto WK; Wong SY; Chan CK; Gu Q; Tong TS; Cheung TK; Chu KM; Wong BC
Helicobacter; 2009 Dec; 14(6):505-11. PubMed ID: 19889067
[TBL] [Abstract][Full Text] [Related]
58. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia.
Erçin CN; Uygun A; Toros AB; Kantarcioğlu M; Kilciler G; Polat Z; Bağci S
Turk J Gastroenterol; 2010 Mar; 21(1):12-6. PubMed ID: 20533106
[TBL] [Abstract][Full Text] [Related]
59. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
[TBL] [Abstract][Full Text] [Related]
60. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial.
Mirbagheri SA; Hasibi M; Abouzari M; Rashidi A
World J Gastroenterol; 2006 Aug; 12(30):4888-91. PubMed ID: 16937475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
